229
Participants
Start Date
October 24, 2019
Primary Completion Date
September 9, 2022
Study Completion Date
September 9, 2022
LOU064
Participants with a UAS7≥16 at Week 12 or Week 16 in the CLOU064A2201, as well as participants who experienced a relapse during the 12-week observational period, were administered LOU064 50mg capsules b.i.d. (i.e. two capsules of LOU064 50mg in the morning and two capsules of LOU064 50mg in the evening) from Day 1 up to Week 52 of the Treatment period.
Novartis Investigative Site, CABA
Novartis Investigative Site, Budapest
Novartis Investigative Site, Copenhagen NV
Novartis Investigative Site, Edegem
Novartis Investigative Site, Liège
Novartis Investigative Site, Debrecen
Novartis Investigative Site, Szolnok
Novartis Investigative Site, Orosháza
Novartis Investigative Site, Pécs
Novartis Investigative Site, Prague
Novartis Investigative Site, Denizli
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Pembroke Pines
Novartis Investigative Site, Istanbul
Novartis Investigative Site, Talas / Kayseri
Novartis Investigative Site, Owensboro
Novartis Investigative Site, Grove City
Novartis Investigative Site, Nantes
Novartis Investigative Site, Ypsilanti
Novartis Investigative Site, Lille
Novartis Investigative Site, St Louis
Novartis Investigative Site, Little Rock
Novartis Investigative Site, Litchfield Park
Novartis Investigative Site, San Diego
Novartis Investigative Site, Mission Viejo
Novartis Investigative Site, Walnut Creek
Novartis Investigative Site, Moscow
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Stavropol
Novartis Investigative Site, CABA
Novartis Investigative Site, La Plata
Novartis Investigative Site, Mendoza
Novartis Investigative Site, Edmonton
Novartis Investigative Site, London
Novartis Investigative Site, Niagara Falls
Novartis Investigative Site, Ottawa
Novartis Investigative Site, Québec
Novartis Investigative Site, Verdun
Novartis Investigative Site, Prague
Novartis Investigative Site, Tábor
Novartis Investigative Site, Arhus C
Novartis Investigative Site, Nice
Novartis Investigative Site, Ichinomiya
Novartis Investigative Site, Funabashi
Novartis Investigative Site, Hiroshima
Novartis Investigative Site, Obihiro
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Itabashi-ku
Novartis Investigative Site, Takaoka
Novartis Investigative Site, Gdansk
Novartis Investigative Site, Lodz
Novartis Investigative Site, Lodz
Novartis Investigative Site, Rzeszów
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Košice
Novartis Investigative Site, Nové Zámky
Novartis Investigative Site, Svidník
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Alicante
Novartis Investigative Site, Leeds
Novartis Investigative Site, London
Novartis Investigative Site, Oxford
Novartis Investigative Site, Plymouth
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY